Effects of GSK v Teva Ripple after SCOTUS Denies Cert
May 23, 2023
By: Ross Blau
Life Sciences IP Review
Axinn associate Ross Blau co-authored the Life Sciences IP Review article, "Effects of GSK v Teva Ripple after SCOTUS Denies Cert."
Click here to access the publication. A subscription is required.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
GCR Live Global: Navigating the Future of Antitrust 2026
Speaking Engagement
Antitrust
Axinn Earns Top Antitrust Rankings Coast to Coast in GCR 100
Awards & Recognitions
Why Should I Care About Property Controls?
Speaking Engagement
Antitrust
What’s the Score, Your Honor? Conversation With Judge Richard Boulware
Podcast
LCA Renaissance Symposium XIX 2025
Speaking Engagement
Antitrust
Stakeholders 25th Annual CYOC Career Development Conference
Sponsorship
Antitrust
Japan Competition Law Update
Axinn Viewpoints
Antitrust
